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The additional mean cost of pemetrexed plus cisplatin therapy,
over cisplatin monotherapy, was A$14,032.78 per patient. The
mean and median survival gain with pemetrexed plus cisplatin
therapy was found to be 0.191 and 0.233 years, respectively, rel-
ative to cisplatin monotherapy, over the 27-month period of
observation. The cost per life-year saved was A$73,470.04 for
mean and A$60,226.52 for median incremental survival. CON-
CLUSION: This survival beneﬁt is a highly patient-relevant
outcome. This economic evaluation found that pemetrexed plus
cisplatin therapy offers an acceptable cost-effectiveness ratio for
a small population of MPM patients in Australia.
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OBJECTIVES: The FDA’s approval of Avastin, Erbitux and other
novel agents has generated debate about the high cost and rela-
tive value of new cancer treatments. We sought to understand
whether oncologists consider the therapies they employ to be
cost-effective and to ascertain oncologists’ cost-effectiveness
thresholds for such therapies. METHODS: We surveyed 139
oncologists at two large academic hospitals in Boston. We asked
respondents to provide estimates for the cost and effectiveness
of Avastin (without appealing to published data) and whether
they thought the treatment offered “good value.” We also asked
respondents to judge how large a gain in life-expectancy would
justify a hypothetical new cancer therapeutic that cost $70,000
per year more than standard care. We used this information to
calculate implied cost-effectiveness thresholds (in QALYs) for
each respondent. Finally, we asked respondents about the role of
cost in their treatment recommendations. RESULTS: Ninety
oncologists (65%) completed the survey. Cost-effectiveness
thresholds, derived from the hypothetical scenario, averaged
over $300,000/QALY. Oncologists’ estimates of the cost and sur-
vival beneﬁt of Avastin implied a cost-effectiveness ratio in the
same range, yet only 25% of oncologists believed Avastin offered
good value. Oncologists who indicated a greater sensitivity to
costs in their prescribing behavior had signiﬁcantly lower cost-
effectiveness thresholds. CONCLUSIONS: Oncologists in an
academic medical setting had implied cost-effectiveness thresh-
olds that were roughly 6 times higher than a commonly cited
standard in the U.S. of $50,000/QALY. When asked about spe-
ciﬁc scenarios, however, oncologists implied that very small gains
in life expectancy were not worth the additional costs. Further,
most oncologists were dubious about whether a recently
approved therapy offered “good value.” As expensive new
cancer therapies enter clinical practice, oncologists’ views about
their role as practitioners may increasingly conﬂict with their
beliefs about the value offered by these therapies.
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OBJECTIVES: To encourage early adoption, Medicare pays a
temporary premium for selected new technologies (which are
called pass-through technologies) in the outpatient setting.
Implicit decisions are being made that the additional money
spent for these pass-through technologies is worthwhile to the
Medicare program. The goal of this study was to examine how
implicit decisions being made for pass-through technologies
compare with explicit cost-effectiveness criteria. METHODS:
We selected as case studies four technologies—two pass-through
devices (embolic capture devices and silicone oil for retinal tam-
ponade) and two pass-through drugs/biologicals (pegﬁlgrastim,
triptorelin pamoate)—that Medicare estimates will account for
the bulk of pass-through spending for 2004. We examined
whether cost-effectiveness literature existed at the time of pass-
through approval and critically examined its quality. We then
used publicly-available data (e.g., Medicare claims and payment
rates) to supplement available studies and examine cost-
effectiveness thresholds from Medicare’s perspective. RESULTS:
Cost-effectiveness studies were available for two of the four case
study technologies at the time of their application review. The
quality was variable. These studies, later publications, and our
own analyses suggest some case study technologies could be cost-
effective in at least a subset of the Medicare population in which
they are used. CONCLUSIONS: Cost-effectiveness information
is sometimes available early in the life cycle of a technology and
may provide additional useful information about whether and
for which subpopulation Medicare should pay a premium for a
new technology. Policy analysts must evaluate cost-effectiveness
information critically, however, and may need to conduct sup-
plemental analyses as a result. Medicare payment decisions do
not now reﬂect any judgment about the value of that technology
in terms of clinical beneﬁt for incremental cost. The challenge to
Medicare is to be able to limit pass-through payments to only
those populations for whom there is proven value.
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OBJECTIVES: To critically evaluate published cost-effectiveness
(CE) models and identify model elements contributing to the
large variability in results. METHODS: A literature search of
MEDLINE and EMBASE from 1985–2004 identiﬁed eight
English-language CE models comparing coxibs to a nonsteroidal
anti-inﬂammatory drug (NSAID)-alone regimen. Two studies
were excluded due to unavailable model input data. Model time
horizons ranged from six months to lifetime, and primary out-
comes ranged from gastrointestinal (GI) events averted to life-
years gained and quality-adjusted life-years gained. Common
elements across models were minor GI discomfort/dyspepsia,
moderate GI events/symptomatic ulcer, and severe GI events.
Only two of the analyses included cardiovascular side effects. To
compare model inputs we standardized all analyses to a six-
month tree structure with the three GI side effects. Study prob-
abilities were converted to six-month rates where necessary 
and costs were converted to $US using the purchasing power
parity index. Cost offsets between coxibs and NSAIDs were cal-
culated by multiplying the probability of the GI event by cost
per event. RESULTS: The relative price used for coxibs com-
pared with NSAIDs differed widely across studies (median over
six months, $156; range, $14–$387). Differences in total GI
event cost offsets were small (median, -$41; range -$53 to 
-$18). Moderate GI events provided the greatest GI event cost
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offset in four of the six studies (median, -$21; range -$35 to 
-$0.50). In one case, the GI event offsets (due to the unusually
high cost of treating minor GI) were greater than the additional
cost of the coxib. CONCLUSIONS: Variation in drug acquisi-
tion cost of NSAIDs relative to coxibs was more important in
contributing to the variation in results but the variations in clin-
ical inputs and in costs of GI events were also important. More
investigation into the reasons for differences in costs and clini-
cal input is needed.
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OBJECTIVES: Although there has been research published on
the topic of medication adherence in chronic obstructive pul-
monary disease (COPD), nothing in the literature describes the
association between patient-reported adherence and clinical out-
comes. This study examines the relationship between two
patient-reported adherence measures and clinical outcomes in
COPD. METHODS: Three-hundred and twenty COPD patients
from seven geographically diverse sites across the United States
were enrolled from April 2003 to November 2003 and admin-
istered both the Morisky Medication Adherence Scale (MMAS)
and Inhaler Adherence Scale (IAS) questionnaires. Subsequently,
retrospective chart review was conducted to collect demo-
graphic, laboratory, and clinical data for each participant. The
association between patient-reported medication adherence and
FEV1 and FEV1 % predicted was determined using both ordi-
nary least squares (OLS) regression and a parametric two-step
sample selection model. RESULTS: Both the MMAS and IAS
indicated the majority of participants appear to be adherent with
their medication regimen. The results derived from the two-step
sample selection model demonstrated that every one-point
increase in IAS score was associated with an increase in both
FEV1 (p = 0.0003) and FEV1 % predicted (p = 0.0008). Pro-
gression of disease was signiﬁcantly associated with a decrease
in both FEV1 (p = 0.004) and FEV1 % predicted (p = 0.041).
Medication adherence, as measured by the MMAS, was not asso-
ciated with a signiﬁcant change in either FEV1 or FEV1 % pre-
dicted. CONCLUSIONS: The IAS appears to be a tool that
clearly demonstrates the association between patient-reported
medication adherence and signiﬁcantly improved clinical out-
comes in COPD. The IAS also appears to be superior to the
MMAS in this respect.
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OBJECTIVE: To examine if method of case ascertainment affects
estimates of the prevalence and severity of dementia in Medicare
nursing home residents. METHODS: A nationally-representative
sample of Medicare beneﬁciaries residing in skilled-nursing facil-
ities (N = 1100) was identiﬁed from the Medicare Current Ben-
eﬁciary Survey (MCBS) for 2001. The MCBS contains detailed
information from medical records and personal interviews on
socio-demographics, health and medical conditions, and health
care use. Survey information can be linked to Medicare claims,
drug administration records, and Minimum Data Set (MDS).
Dementia prevalence rates were determined using following four
sources of diagnosis information, alone and in combinations:
survey, MDS, Medicare claims, and drugs for dementia treat-
ment. Concordance between sources for dementia diagnosis was
measured as percent agreement and with kappa statistics. The
severity of dementia cases from each source was determined
using cognitive, physical, and behavioral functioning limitation
measures from MDS. Chi-square tests were performed to iden-
tify statistically signiﬁcant differences at p < 0.05. RESULTS:
Among four measures considered singly, the lowest dementia
rates were obtained using drugs (12.4%) and the highest using
claims (57.3%). Rates were higher when sources were combined
and reached 68% using all four sources together. As for con-
cordance, the percent agreement ranged from a low of 19.2%
between claims and drugs to a high of 97.5% between drugs and
claims with survey or MDS. Kappa statistics were the lowest
between drugs and survey or MDS with claims (kappa 0.12), and
were highest between survey and MDS (kappa 0.70). Sources
were similar in the severity of dementia cases. CONCLUSIONS:
Although there was a wide variation in prevalence and concor-
dance of dementia cases by diagnostic source, there was no sys-
tematic bias based on disease severity. A combination of all 
four sources presents the most inclusive measure of disease
prevalence available to researchers working on dementia in 
long-term care.
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OBJECTIVES: The purpose of this study was to illustrate how
decision-making could be affected by the choice of preference-
based algorithms for the SF-36 and SF-12, and provide some
guidance on selecting an appropriate algorithm. METHODS:
Two sets of data were used: 1) a clinical trial of adult asthma
patients; and 2) a longitudinal study of post-stroke patients.
Incremental costs were assumed to be $2000 per year over stan-
dard treatment, and QALY gains realized over a 1-year period.
Ten published algorithms were identiﬁed, denoted by ﬁrst
author: Brazier (SF-36), Brazier (SF-12), Shmueli, Fryback,
Lundberg, Nichol, Franks (3 algorithms), and Lawrence. Incre-
mental cost-utility ratios (ICURs) for each algorithm, stated in
dollars per quality-adjusted life year ($/QALY), were ranked and
compared between datasets. RESULTS: In the asthma pati-
ents, ICURs ranged from Lawrence’s SF-12 algorithm at
$30,769/QALY to Brazier’s SF-36 algorithm at $63,492/QALY.
ICURs for the stroke cohort varied slightly more dramatically.
The MEPS-based algorithm by Franks et al. provided the lowest
ICUR at $27,972/QALY. The Fryback and Shmueli algorithms
provided ICURs that were greater than $50,000/QALY. The
ICUR-based ranking of algorithms was strongly correlated
between the asthma and stroke datasets (r = 0.69). CONCLU-
SIONS: SF-36/SF-12 preference-based algorithms produced a
wide range of ICURs that could potentially lead to different
reimbursement decisions. Brazier’s SF-36 and SF-12 algorithms
have a strong methodological and theoretical basis and tended
to generate relatively higher ICUR estimates, considerations that
support a preference for this algorithm over the alternatives. The
“second-generation” algorithms developed from preferences
mapped from other indirect preference-based measures tended to
generate lower ICURs that would promote greater adoption of
new technology. There remains a need for an SF-36/SF-12 pref-
erence-based algorithm based on the US general population that
has strong theoretical and methodological foundations.
